Coronavirus vaccine is an inactivated virus vaccine and is being developed by Sanofi pasteur (formerly Aventis Pasteur) for the preventive treatment of COVID-2019 infections. The development of the vaccine will be based on the prior preclinical studies done on a Severe Acute Respiratory Syndrome (SARS) vaccine candidate and will be done in collaboration with Biomedical Advanced Research And Development Authority (BARDA). Sanofi Pasteur will utlilise its recombinant DNA platform, that produces an exact genetic match to proteins that are found on the surface of the coronavirus. The DNA of baculovirus expression platform will be combined with the DNA sequence encoding the coronavirus antigen. The large quantities of coronavirus antigen generated will in turn be formulated to stimulate the immune system and protect against the virus. Preclinical development is underway in the US.
Earlier Sanofi Pasteur was collaborating with the US National Institute of Allergy and Infectious Diseases (NIAID) to research and develop a SARS vaccine. However, NIAID is no more involved in the development of the vaccine and the development in SARS indication is discontinued.
In January 2005, Aventis Pasteur changed its name to sanofi pasteur.
In February 2020, Sanofi and US Department of Health and Human Services entered into an agreement to advance the development of a coronavirus vaccine based on Sanofi's previous development work for serious acute respiratory syndrome (SARS) vaccine. Sanofi will work in collaboration with Biomedical Advanced Research And Development Authority (BARDA) and utlilise its recombinant DNA platform, which produces an exact genetic match to proteins that are found on the surface of the coronavirus. 
Aventis Pasteur (later sanofi pasteur) had entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to research and develop an inactivated coronavirus vaccine against Severe Acute Respiratory Syndrome (SARS). Under the agreement, which was signed on 26 September 2003, sanofi pasteur would develop the vaccine candidate using a similar approach to that of the licensed inactivated polio vaccine.
Key Development Milestones
In February 2020, Sanofi announced that the preclinical studies done by Protein Sciences (acquired by Sanofi), prior to 2017, on the SARS vaccine candidate was immunogenic and afforded partial protection in animal challenge models. These results will form a basis for further development of Coronavirus vaccine  .
Sanofi pasteur is also participating in the Canadian SARS Research Consortium, a public-private effort to coordinate, promote and support research on SARS, including vaccine development  .